Dimethyl Fumarate clinical trials
Also written Tecfidera, BG00012 and FP187.
How each study uses Dimethyl Fumarate is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Dimethyl Fumarate studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 27 Mar 2013 · TECFIDERA · NDA 204063 (FDA, Drugs@FDA)
- European Union
- 30 Jan 2014 · Tecfidera · EMEA/H/C/002601 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
59 studies that test it; most in 2015 (16)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 3 |
| 2013 | 4 |
| 2014 | 4 |
| 2015 | 16 |
| 2016 | 9 |
| 2017 | 2 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 4 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 37 · Other 22
Biogen (33) · Xuanwu Hospital, Beijing (4) · Multiple Sclerosis Center of Northeastern New York (2) · Almirall, S.A. (2) · Forward-Pharma GmbH (2) · Pujol, Aurora, M.D. (1) · Beijing Tiantan Hospital (1) · Universitätsmedizin Mannheim (1)
Often tested with
Tested in the same studies.
Aspirin (2) · Fingolimod (2) · Temozolomide (1) · Diroximel fumarate (1) · Adrenal Cortex Hormones (1) · Hydroxychloroquine (1) · Azithromycin (1) · Tocilizumab (1)
Related medicines
As reviewed, each with the page that says it.
- One of Immunosuppressive Agents source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Dimethyl Fumarate.
- Apr 2027Long-Term Analysis of DImethyl Fumarate, to Slow the Growth of Areas of Geographic AtrophyPhase 2 · Assistance Publique - Hôpitaux de Paris
Studies
Open first, then newest update. How each study uses Dimethyl Fumarate is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 59
- Randomised Evaluation of COVID-19 TherapyRecruitingPhase 3University of OxfordNCT04381936Written as Dimethyl fumarate
- A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)Not yet recruitingPhase 3BiogenNCT07483632Written as Dimethyl Fumarate
- Long-Term Analysis of DImethyl Fumarate, to Slow the Growth of Areas of Geographic AtrophyRecruitingPhase 2Assistance Publique - Hôpitaux de ParisNCT04292080Written as Dimethyl Fumarate (TECFIDERA™)
- Dimethyl Fumarate Treatment for Intracranial Unruptured Aneurysms.CompletedPhase 4Beijing Tiantan HospitalNCT05959759Written as Dimethyl fumarate
- Dimethyl Fumarate in AdrenomyeloneuropathyActive, not recruitingPhase 2/3Pujol, Aurora, M.D.NCT06513533Written as Dimethyl fumarate
- Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)CompletedPhase 3BiogenNCT02283853Written as dimethyl fumarate
- A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in ChinaCompletedPhase 4BiogenNCT05658484Written as Dimethyl fumarate
- Impact of an Immune Modulator Dimethyl Fumarate on Acute Ischemic StrokeTerminatedPhase 1/2Xuanwu Hospital, BeijingNCT04890353Written as Dimethyl fumarate
- Dimethyl Fumarate for the Treatment of Intracerebral HemorrhageWithdrawnPhase 2Xuanwu Hospital, BeijingNCT04890379Written as Dimethyl fumarate
- Combination of the Immune Modulator Dimethyl Fumarate With Intraarterial Treatment in Acute Ischemic StrokeWithdrawnPhase 2Xuanwu Hospital, BeijingNCT04891497Written as Dimethyl Fumarate
- Efficacy and Safety of BG00012 in MSCompletedPhase 2BiogenNCT00168701Written as BG00012
- Alternate Dosing Regimens of BG00012 in Healthy VolunteersCompletedPhase 1BiogenNCT01281111Written as Dimethyl Fumarate (BG00012)
- Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric ParticipantsTerminatedPhase 3BiogenNCT03870763Written as Dimethyl Fumarate
- Study on Therapy With Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL)CompletedPhase 2Universitätsmedizin MannheimNCT02546440Written as Dimethyl fumarate
- Combination of the Immune Modulator Dimethyl Fumarate With Alteplase in Acute Ischemic StrokeStatus unknownPhase 1/2Xuanwu Hospital, BeijingNCT04890366Written as Dimethyl Fumarate
- Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS)CompletedPhase 4University of Texas Southwestern Medical CenterNCT02739542Written as Tecfidera
- Dimethyl Fumarate (DMF) in Systemic Sclerosis-Associated Pulmonary Arterial HypertensionTerminatedPhase 1Robert LafyatisNCT02981082Written as Dimethyl Fumarate (DMF)
- Tecfidera and the Gut MicrobiotaCompletedPhase 4BiogenNCT02471560Written as dimethyl fumarate
- BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)CompletedPhase 3BiogenNCT00835770Written as dimethyl fumarate
- Dimethyl Fumarate Treatment of Primary Progressive Multiple SclerosisCompletedPhase 2Rigshospitalet, DenmarkNCT02959658Written as Dimethyl fumarate
See all 59 studies that test Dimethyl Fumarate →
Given beside what is tested · 3 — Dimethyl Fumarate is usual care or a partner of the new treatment
- Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving TecfideraCompletedPhase 4BiogenNCT02410278Written as dimethyl fumarate
- Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple SclerosisCompletedPhase 4BiogenNCT02090413Written as dimethyl fumarate
- PeptoBismol® Use to Reduce Gastrointestinal Events in Healthy Volunteers Receiving DMF [Tecfidera®] Twice DailyCompletedPhase 1BiogenNCT01915901Written as dimethyl fumarate (DMF)
As the comparator · 8 — what is tested is compared with Dimethyl Fumarate
- A Study of Rocbrutinib in PRL-Positive Relapsing-Remitting Multiple SclerosisRecruitingPhase 2Guangzhou Lupeng Pharmaceutical Company LTD.NCT07776743Written as Dimethyl Fumarate
- A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple SclerosisTerminatedPhase 2EMD Serono Research & Development Institute, Inc.NCT02975349Written as Tecfidera
- IMCY-0141 Safety and Efficacy in Multiple Sclerosis - ISEMIS StudyActive, not recruitingPhase 1/2Imcyse SANCT05417269Written as Dimethyl Fumarate
- Comparative Bioavailability of BAFIERTAM™ (Monomethyl Fumarate) and Tecfidera® (Dimethyl Fumarate) in Healthy SubjectsCompletedPhase 1Banner Life Sciences LLCNCT04570670Written as dimethyl fumarate 240 mg
- A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2CompletedPhase 3BiogenNCT03093324Written as Dimethyl Fumarate
- Study to Compare GI Tolerability Following Oral Administration of Bafiertam™ or Tecfidera to Healthy VolunteersCompletedPhase 1Banner Life Sciences LLCNCT04022473Written as Tecfidera
- A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic TherapyCompletedPhase 3AbbVieNCT03255382Written as Fumaderm
- The Influence of Adalimumab on Cardiovascular and Metabolic Risk in PsoriasisStatus unknownPhase 4Medical University of ViennaNCT01088165Written as Fumaric acid esters treatment group
Codes
What other systems call Dimethyl Fumarate · ClinicalTrials.gg INT006590
- MeSH (NLM) D000069462Dimethyl FumarateConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) FO2303MNI2DIMETHYL FUMARATEConfirmed FDA, NLM, Wikidata
- RxNorm 1373478Confirmed FDA, Wikidata
- Wikidata Q418123dimethyl fumarateConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C63670Dimethyl FumarateOne source FDA
- DrugBank DB08908One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000069462 | Dimethyl Fumarate | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | FO2303MNI2 | DIMETHYL FUMARATE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1373478 | — | Confirmed FDA, Wikidata |
| Wikidata | Q418123 | dimethyl fumarate | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C63670 | Dimethyl Fumarate | One source FDA |
| DrugBank | DB08908 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.